Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals

BMC Immunology

Volumn 13, Issue , 2012, Pages

  Kelly, Deborah ^a,b   Burt, Kimberley ^b   Missaghi, Bayan ^a,b   Barrett, Lisa ^c   Keynan, Yoav ^d,e   Fowke, Keith ^d,e   Grant, Michael ^a,f  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Eastern Health Canada   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

A California 07 2009 H1N1 HA antigen; Age; AS03 oil in water adjuvant; CD4+ T cells; HIV; Inflammation; Influenza; Pandemic

Indexed keywords

ANTIRETROVIRUS AGENT; INFLUENZA VACCINE;

ADULT; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PANDEMIC INFLUENZA; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, VIRAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HIV; HIV INFECTIONS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PANDEMICS; VIRAL LOAD;

EID: 84865531798     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-13-49     Document Type: Article

References (22)

1. Public Health Agency of Canada Guidance document on the use of pandemic influenza A(H1N1) 2009 inactivated monovalent vaccine 2009, Ottawa: Government of Canada, Revised Nov. 20, 2009, Public Health Agency of Canada.
2. Zanetti AR, Amendola A, Besana S, Boschini A, Tanzi E. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine 2002, 20(Suppl 5):B29-B32.
3. GlaxoSmithKline Arepanrix, AS03-adjuvanted H1N1 pandemic influenza vaccine, emulsion for injection, product information leaflet 2009, Mississauga: Capao1/pil, 10, GlaxoSmithKline.
4. Aglukaak L, . Canadian Minister of Health Interim order respecting the sale of the vaccine for the novel influenza H1N1 virus Ottawa: Government of Canada, October 13, 2009, Canadian Minister of Health.
5. Li H, Willingham SB, Ting JP, Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. J Immunol 2008, 181:17-21. 2587213, 18566365.
6. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, Kielland A, Chomez P, Garcon N, Van Mechelen M. Adjuvant system AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473. 10.1016/j.vaccine.2011.01.011, 21256188.
7. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina M, Nguyen-Van-Tam JS, Read RC, Warren FC, Zambon M. A randomized, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. Health Technol Assess 2010, 14:193-334.
8. Cooper C. Pandemic H1N1 2009 influenza and HIV: a review of natural history, management and vaccine immunogenicity. Curr Opin Infect Dis 2012, 25:26-35. 10.1097/QCO.0b013e32834ef56c, 22183114.
9. Tremblay C, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, Sekaly R-P, Boivin G. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine. Vaccine 2011, 29:1359-1363. 10.1016/j.vaccine.2010.12.023, 21185423.
10. Vlachopoulos C, Xaplanteris P, Sambatakou H, Mariolis E, Bratsas A, Christoforatou E, Miliou A, Aznaourdis K, Stefanadis C. Acute systemic inflammation induced by Influenza A (H1N1) vaccination causes a deterioration in endothelial function in HIV- infected Patients. HIV Med 2011, 10:594-601.
11. Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep 2007, 4:42-47. 10.1007/s11904-007-0007-8, 17338860.
12. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008, 214:231-241. 10.1002/path.2276, 18161758.
13. Keynan Y, Bodnarchuk T, Wayne S, Li Y, Fowke KR. Evaluation of influenza-specific humoral response by microbead array analysis. Can J Infect Dis Med Micro 2011, 22:25-29.
14. Bickel M, Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, Von Hentig N, Herrmann E, Doerr HW, Brodt HR, Allwinn R. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS 2010, 24:31-35.
15. Cooper C, Klein M, Walmsley S, Haase D, MacKinnon-Cameron D, Marty K, Li Y, Smith B, Halperin S, Law B, Scheifele D, . PHAC CIHR Influenza Research Network High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster in a randomized trial of HIV-infected adults. HIV Clin Trials 2012, 13:23-32. 10.1310/hct1301-23, 22306585, PHAC CIHR Influenza Research Network.
16. Launay O, Desaint C, Durier C, Loulerque P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, Ajana F, Colinde Verdiere N, Reynes J, Foubert V, Roman F, Devaster JM, Delfraissy JF, Aboulker JP, . ANRS 151 HIFLUVAC Study group and the French Clinical Vaccinology Network Safety and Immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis 2011, 204:124-134. 10.1093/infdis/jir211, 3307156, 21628666, ANRS 151 HIFLUVAC Study group and the French Clinical Vaccinology Network.
17. Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR. Response to 2009 pandemic and seasonal influenza vaccines co- administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Vaccine 2011, 29:9209-9213. 10.1016/j.vaccine.2011.09.103, 21974995.
18. Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, Pellicciotta G, Monti A, Mascagni P, Moro M, Vicenzi E. Induction of protective antibody response by MF59- adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011, 25:177-183. 10.1097/QAD.0b013e328341afa8, 21150561.
19. Bickel M, von Hentig N, Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, Herrmann E, Doerr HW, Brodt HR, Allwinn R. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-infected patients. Clin Infect Dis 2011, 52:122-127. 10.1093/cid/ciq003, 21148530.
20. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504. 10.1016/S1473-3099(09)70175-6, 2775097, 19628174.
21. Calmy A, Bel M, Nguyen A, Combescure C, Delhumeau C, Meier S, Yerly S, Kaiser L, Hirschel B, Siegrist CA, . H1N1 study group Strong serological responses and HIV RNA increased following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med 2012, 13:217-218. H1N1 study group.
22. El Sahly HM, Davis C, Kotloff K, Meier J, Winokur PL, Wald A, Johnston C, George SL, Brady RC, Lehmann C, Stokes-Riner A, Keite WA. Higher antigen content improves the immune responses to 2009 H1N1 influenza vaccine in HIV-infected adults: A randomized clinical trial. J Infect Dis 2012, 205:703-712. 10.1093/infdis/jir837, 22275399.